Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR T-cell Therapy in Refractory or Relapsed T-cell Malignancies
NCT06316427Phase 2Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Mar 2024
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of CD7-CART in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL) (3 arms), sponsored by Beijing Gaobo Hospital. Primary endpoints: Dose-Limiting Toxicity at 21 days and Overall Response Rate at 3 months. Started Mar 2024; status: recruiting.
02
Drugs
CD7-CART
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT06316427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06316427.